[HTML][HTML] Unmet needs of chronic hepatitis C in the era of direct-acting antiviral therapy
CF Huang, ML Yu - Clinical and molecular hepatology, 2020 - ncbi.nlm.nih.gov
The treatment of chronic hepatitis C (CHC) has been revolutionized in an era of all-oral
direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can …
direct-acting antivirals (DAAs) since 2014. Satisfactory treatment efficacy and tolerability can …
Direct antiviral therapy for hepatitis C cirrhotic patients in liver transplantation settings: a systematic review
J Li, V Wu, CQ Pan - Hepatology International, 2022 - Springer
Abstract Background Hepatitis C (HCV)-induced decompensated cirrhosis warrants liver
transplantation (LT) as the only ultimate solution. These patients experience liver …
transplantation (LT) as the only ultimate solution. These patients experience liver …
Brazilian society of hepatology updated recommendations for diagnosis and treatment of hepatocellular carcinoma
AL Chagas, AA MATTOS, FJ Carrilho… - Arquivos de …, 2020 - SciELO Brasil
Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related mortality
worldwide. The Brazilian Society of Hepatology (SBH) published in 2015 its first …
worldwide. The Brazilian Society of Hepatology (SBH) published in 2015 its first …
Post liver transplant recurrent and de novo viral infections
D Jothimani, R Venugopal, M Vij, M Rela - Best Practice & Research …, 2020 - Elsevier
Survival following liver transplantation has changed dramatically owing to improvement in
surgical techniques, peri-operative care and optimal immunosuppressive therapy. Post-Liver …
surgical techniques, peri-operative care and optimal immunosuppressive therapy. Post-Liver …
Non‐invasive assessment of fibrosis regression and portal hypertension in patients with advanced chronic hepatitis C virus (HCV)‐associated liver disease and …
V Knop, D Hoppe, J Vermehren… - Journal of viral …, 2021 - Wiley Online Library
Long‐term effects on cirrhosis and portal hypertension of direct antiviral agent (DAA)‐based
eradication of hepatitis C virus (HCV) are still under debate. We analysed dynamics of liver …
eradication of hepatitis C virus (HCV) are still under debate. We analysed dynamics of liver …
Danoprevir for the treatment of hepatitis C virus infection: design, development, and place in therapy
M Miao, X Jing, E De Clercq, G Li - Drug Design, Development and …, 2020 - Taylor & Francis
Abstract On June 8, 2018, an NS3/4A protease inhibitor called danoprevir was approved in
China to treat the infections of HCV genotype (GT) 1b–the most common HCV genotype …
China to treat the infections of HCV genotype (GT) 1b–the most common HCV genotype …
Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time
L Cuypers, F Ceccherini‐Silberstein… - Reviews in Medical …, 2016 - Wiley Online Library
The introduction of highly potent direct‐acting antivirals (DAAs) has revolutionized hepatitis
C virus treatment. Nevertheless, viral eradication worldwide remains a challenge also in the …
C virus treatment. Nevertheless, viral eradication worldwide remains a challenge also in the …
[HTML][HTML] Hepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center study
A Ferrarese, G Germani, M Gambato… - World Journal of …, 2018 - ncbi.nlm.nih.gov
AIM To evaluate waiting list (WL) registration and liver transplantation (LT) rates in patients
with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals …
with hepatitis C virus (HCV)-related cirrhosis since the introduction of direct-acting antivirals …
Impact of new direct-acting antiviral drugs on hepatitis C virus-related decompensated liver cirrhosis
M Essa, A Sabry, E Abdelsameea… - European journal of …, 2019 - journals.lww.com
Background The benefits of treatment of hepatitis C virus with direct-acting antiviral drugs in
patients with decompensated liver cirrhosis (DLC) are still unclear. Aim To evaluate the …
patients with decompensated liver cirrhosis (DLC) are still unclear. Aim To evaluate the …
Second generation direct-acting antivirals–do we expect major improvements?
JJ Feld, GR Foster - Journal of hepatology, 2016 - Elsevier
The rapid progress in the development of direct-acting antiviral agents for hepatitis C has
allowed the vast majority of patients to receive all oral therapy that will eliminate their virus …
allowed the vast majority of patients to receive all oral therapy that will eliminate their virus …